Clinical Trial Update: Study of Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorder [Phase 2]

View source ↗

Summary

Phase 2 clinical trial update on triheptanoin for long-chain fatty acid oxidation disorders with results posted in 2017.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Carnitine Palmitoyltransferase Ii Deficiency
• Long-chain 3-hydroxyacyl-coa Dehydrogenase Deficiency
• Mitochondrial Trifunctional Protein Deficiency
• Very Long-chain Acyl-coa Dehydrogenase Deficiency

Drugs mentioned

• Triheptanoin (triheptanoin)

Snippet

Sponsor: Oregon Health and Science University | Conditions: Very Long-chain acylCoA Dehydrogenase (VLCAD) Deficiency, Carnitine Palmitoyltransferase 2 (CPT2) Deficiency | Phase 2 | Status: COMPLETED | Results posted: 2017-03-23